From 6f852dbe1acc83ad1fdbb8afb36c1775596df775 Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Mon, 30 Mar 2026 04:33:26 +0000 Subject: [PATCH 1/5] extract: 2026-03-30-lords-ada-lovelace-ai-governance-submission-gai0086 Pentagon-Agent: Epimetheus <3D35839A-7722-4740-B93D-51157F7D5E70> --- ...ment-indicating-behavioral-sdoh-failure.md | 34 +++++++++++++++++++ ...s-with-inflammation-as-primary-mediator.md | 33 ++++++++++++++++++ ...velace-ai-governance-submission-gai0086.md | 13 ++++++- 3 files changed, 79 insertions(+), 1 deletion(-) create mode 100644 domains/health/hypertension-related-cvd-mortality-doubled-2000-2023-despite-available-treatment-indicating-behavioral-sdoh-failure.md create mode 100644 domains/health/semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss-with-inflammation-as-primary-mediator.md diff --git a/domains/health/hypertension-related-cvd-mortality-doubled-2000-2023-despite-available-treatment-indicating-behavioral-sdoh-failure.md b/domains/health/hypertension-related-cvd-mortality-doubled-2000-2023-despite-available-treatment-indicating-behavioral-sdoh-failure.md new file mode 100644 index 000000000..37dacbb0b --- /dev/null +++ b/domains/health/hypertension-related-cvd-mortality-doubled-2000-2023-despite-available-treatment-indicating-behavioral-sdoh-failure.md @@ -0,0 +1,34 @@ +--- +type: claim +domain: health +description: Age-standardized hypertensive disease mortality rose from 23 to 43+ per 100,000 during the same period ischemic heart disease mortality declined, with midlife adults (35–64) showing the most pronounced increases +confidence: likely +source: JACC Data Report 2025, JACC Cardiovascular Statistics 2026, Hypertension journal 2000-2019 analysis +created: 2026-03-30 +attribution: + extractor: + - handle: "vida" + sourcer: + - handle: "jacc-data-report-authors" + context: "JACC Data Report 2025, JACC Cardiovascular Statistics 2026, Hypertension journal 2000-2019 analysis" +--- + +# Hypertension-related cardiovascular mortality nearly doubled in the United States 2000–2023 despite the availability of effective affordable generic antihypertensives indicating that hypertension management failure is a behavioral and social determinants problem not a pharmacological availability problem + +The JACC Data Report analyzing 1999–2023 US cardiovascular disease mortality trends reveals a critical divergence: while ischemic heart disease mortality declined during the statin era, hypertensive disease mortality nearly doubled from approximately 23 per 100,000 in 2000 to 43 per 100,000 in 2019, contributing to approximately 664,000 deaths in 2023 as primary or contributing cause. This increase was most pronounced in middle-aged adults (ages 35–64). + +This divergence is mechanistically revealing. Effective, affordable, generic antihypertensive medications have been widely available throughout this period—the pharmacological tools exist and are accessible. Yet mortality doubled. This cannot be explained by pharmacological ceiling (the drugs work), access barriers (they're generic and cheap), or knowledge gaps (hypertension management is well-established). + +The failure must therefore be rooted in behavioral and social determinants: medication adherence, dietary patterns, stress, healthcare engagement, and the social conditions that shape these behaviors. The simultaneous success of lipid management (statins) and failure of blood pressure management (antihypertensives) during the same period, in the same population, using the same healthcare delivery system, isolates the mechanism: when treatment requires sustained behavioral change and consistent medication adherence, SDOH factors dominate outcomes even when pharmacological solutions are available and affordable. + +This provides the strongest single empirical case for the claim that medical care explains only 10-20% of health outcomes, because we have a natural experiment where the medical intervention exists, is proven effective, is widely accessible, and yet population-level mortality doubled. + +--- + +Relevant Notes: +- [[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]] +- [[Americas declining life expectancy is driven by deaths of despair concentrated in populations and regions most damaged by economic restructuring since the 1980s]] +- [[Big Food companies engineer addictive products by hacking evolutionary reward pathways creating a noncommunicable disease epidemic more deadly than the famines specialization eliminated]] + +Topics: +- [[_map]] diff --git a/domains/health/semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss-with-inflammation-as-primary-mediator.md b/domains/health/semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss-with-inflammation-as-primary-mediator.md new file mode 100644 index 000000000..93d7dfbd7 --- /dev/null +++ b/domains/health/semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss-with-inflammation-as-primary-mediator.md @@ -0,0 +1,33 @@ +--- +type: claim +domain: health +description: SELECT trial prespecified analysis shows GLP-1 CV protection operates primarily through inflammation reduction rather than weight-mediated mechanisms +confidence: likely +source: Deanfield et al., SELECT investigators, The Lancet November 2025; Colhoun/Lincoff ESC 2024 mediation analysis +created: 2026-03-30 +attribution: + extractor: + - handle: "vida" + sourcer: + - handle: "deanfield-et-al.-(select-investigators)" + context: "Deanfield et al., SELECT investigators, The Lancet November 2025; Colhoun/Lincoff ESC 2024 mediation analysis" +--- + +# Semaglutide's cardiovascular benefit is approximately 67-69% independent of weight or adiposity change, with anti-inflammatory pathways (hsCRP) accounting for more of the benefit than weight loss + +The SELECT trial prespecified analysis (N=17,604, semaglutide 2.4mg weekly vs placebo) found no evidence that semaglutide's MACE reduction was mediated by time-varying weight loss. The benefit was consistent across ALL baseline BMI and waist circumference categories, with no treatment heterogeneity by adiposity level. Approximately 33% of MACE reduction was explained by early reductions in waist circumference, leaving ~67% independent of adiposity/weight change. + +The complementary ESC 2024 mediation analysis by Colhoun/Lincoff found body weight mediated only 19.5% of CV benefit, while hsCRP (inflammation marker) mediated 42.1% - more than double the weight contribution. Joint mediation of all measured metabolic and adiposity parameters explained only 31.4% of benefit (95% CI: -30.1% to 143.6%), leaving ~68.6% pleiotropic/unexplained. + +The convergence of two independent analyses on 67-69% weight-independence is striking. This suggests GLP-1 agonists are fundamentally anti-inflammatory cardiovascular drugs that happen to also cause weight loss, rather than weight-loss drugs that incidentally reduce CVD risk. The mechanism operates through pathways that are independent of adiposity reduction - likely direct effects on inflammatory cascades, endothelial function, and vascular biology. + +This has major implications: (1) the drug should benefit patients across the BMI spectrum, not just high-BMI populations, (2) access barriers are blocking a drug that works via anti-inflammatory mechanisms that address SDOH-generated CVD risk, not just metabolic pathways, and (3) the therapeutic framing needs to shift from 'obesity drug with CV benefits' to 'CV drug that also treats obesity.' + +--- + +Relevant Notes: +- [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] +- [[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]] + +Topics: +- [[_map]] diff --git a/inbox/queue/2026-03-30-lords-ada-lovelace-ai-governance-submission-gai0086.md b/inbox/queue/2026-03-30-lords-ada-lovelace-ai-governance-submission-gai0086.md index 9f3fe1d12..a39a4898d 100644 --- a/inbox/queue/2026-03-30-lords-ada-lovelace-ai-governance-submission-gai0086.md +++ b/inbox/queue/2026-03-30-lords-ada-lovelace-ai-governance-submission-gai0086.md @@ -7,10 +7,13 @@ date: 2026-03-01 domain: health secondary_domains: [ai-alignment] format: policy-submission -status: unprocessed +status: enrichment priority: medium tags: [Lords-inquiry, NHS-AI, clinical-AI, governance, regulatory-capture, Ada-Lovelace-Institute, safety, UK, personalised-medicine] flagged_for_theseus: ["Clinical AI governance submission from major UK AI safety institute — may be relevant to AI alignment domain on regulatory capture patterns"] +processed_by: vida +processed_date: 2026-03-30 +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -62,3 +65,11 @@ The Ada Lovelace Institute is the UK's leading independent research institute on PRIMARY CONNECTION: Session 14 claim candidate on "regulatory capture as sixth institutional failure mode" WHY ARCHIVED: First confirmed safety-oriented submission to the Lords inquiry, before April 20 deadline. Moderates the pure "regulatory capture" framing — safety evidence is entering the record. EXTRACTION HINT: Do not extract now. Read the full submission after April 20. The key question: does the ALI submission explicitly reference the clinical AI failure mode literature (automation bias, de-skilling, NOHARM)? If yes, that's a distinct extractable claim: "institutional acknowledgment of clinical AI failure modes reached Parliament via Lords inquiry." If no, the submission is less notable. + + +## Key Facts +- Ada Lovelace Institute submission reference number is GAI0086 +- Lords Science & Technology Committee NHS AI inquiry launched March 10, 2026 +- Submissions deadline is April 20, 2026 (21 days from March 30, 2026) +- Ada Lovelace Institute was founded in 2018 with Nuffield Foundation funding +- Full submission text is accessible at committees.parliament.uk but was not retrieved in this session -- 2.45.2 From 68ca7db2c8ae60da69828a69ca344948a1373997 Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Mon, 30 Mar 2026 04:45:32 +0000 Subject: [PATCH 2/5] pipeline: archive 1 source(s) post-merge Pentagon-Agent: Epimetheus <3D35839A-7722-4740-B93D-51157F7D5E70> --- ...velace-ai-governance-submission-gai0086.md | 64 +++++++++++++++++++ 1 file changed, 64 insertions(+) create mode 100644 inbox/archive/health/2026-03-30-lords-ada-lovelace-ai-governance-submission-gai0086.md diff --git a/inbox/archive/health/2026-03-30-lords-ada-lovelace-ai-governance-submission-gai0086.md b/inbox/archive/health/2026-03-30-lords-ada-lovelace-ai-governance-submission-gai0086.md new file mode 100644 index 000000000..dd720dafa --- /dev/null +++ b/inbox/archive/health/2026-03-30-lords-ada-lovelace-ai-governance-submission-gai0086.md @@ -0,0 +1,64 @@ +--- +type: source +title: "Ada Lovelace Institute Written Evidence to Lords Science & Technology Committee NHS AI Personalised Medicine Inquiry (GAI0086)" +author: "Ada Lovelace Institute" +url: https://committees.parliament.uk/writtenevidence/113850/html/ +date: 2026-03-01 +domain: health +secondary_domains: [ai-alignment] +format: policy-submission +status: processed +priority: medium +tags: [Lords-inquiry, NHS-AI, clinical-AI, governance, regulatory-capture, Ada-Lovelace-Institute, safety, UK, personalised-medicine] +flagged_for_theseus: ["Clinical AI governance submission from major UK AI safety institute — may be relevant to AI alignment domain on regulatory capture patterns"] +--- + +## Content + +**Written evidence submitted by the Ada Lovelace Institute** (reference GAI0086) to the House of Lords Science and Technology Committee inquiry on "Innovation in the NHS: Personalised Medicine and AI." + +**Inquiry context:** +- Launched: March 10, 2026 +- Submissions deadline: April 20, 2026 (21 days from today's session) +- Committee framing: Why does the NHS struggle to ADOPT life sciences innovations? What systemic barriers prevent deployment? +- The framing is adoption-acceleration, not safety evaluation + +**Ada Lovelace Institute submission framing:** +- "Welcoming the Committee's investigation of the current state of AI governance in the UK" +- Describes "a bird's eye view of the challenges at play" +- Frames the evidence around governance challenges, not just adoption barriers +- ALI's prior work includes "algorithmic impact assessment in healthcare" (separate ALI project) + +**Significance:** +The Ada Lovelace Institute is the UK's leading independent research institute on AI governance and ethics. Its submission framing ("AI governance," "challenges at play") is distinct from the pure adoption-acceleration framing that dominates the inquiry brief. This is the first confirmed submission from a safety-oriented institution in the inquiry record. + +**What is NOT yet known (full submission not accessible):** +- Whether the ALI submission explicitly references clinical AI failure mode literature (automation bias, de-skilling, NOHARM omission dominance) +- Whether the ALI recommends specific safety requirements or merely process improvements +- What specific governance challenges the submission identifies + +**Note:** The April 20 deadline has not yet passed. More submissions are expected before the deadline. + +## Agent Notes + +**Why this matters:** Session 14 documented the Lords inquiry as framed in adoption-acceleration terms — a potential sixth institutional failure mode (regulatory capture). This submission from Ada Lovelace Institute is evidence that the safety perspective IS entering the inquiry record, which complicates the "regulatory capture" framing. The claim that the Lords inquiry represents pure regulatory capture may need nuance: the framing is adoption-biased, but safety evidence is being submitted. The committee's final conclusions (expected months from now) will determine whether safety evidence was incorporated or sidelined. + +**What surprised me:** The submission was filed BEFORE the April 20 deadline, suggesting ALI actively engaged with the inquiry rather than waiting for the deadline. The URL is directly accessible (committees.parliament.uk is open access), which means future sessions can read the full submission content. + +**What I expected but didn't find:** Full submission text (not retrieved this session — URL is accessible but full content not scraped). The follow-up priority is to READ the full submission content after April 20 when more submissions have arrived. + +**KB connections:** +- [[healthcare AI regulation needs blank-sheet redesign because the FDA drug-and-device model built for static products cannot govern continuously learning software]] — ALI's governance framing is likely aligned with this claim +- Session 14 claim candidate: "Regulatory capture as sixth clinical AI institutional failure mode — coordinated global pattern Q1 2026" — this submission is a partial moderator + +**Extraction hints:** Do NOT extract as a standalone claim. The full submission content is needed first. Archive now so the extractor knows: +1. The submission exists and is accessible +2. The framing is governance-oriented (moderates "pure regulatory capture" claim) +3. After April 20, full submissions should be read and more definitive evidence extracted + +**Context:** The Ada Lovelace Institute was founded in 2018 with Nuffield Foundation funding. It has become one of the most influential AI governance voices in the UK. It previously submitted evidence to the government's AI safety review. The fact that it has framed this submission around governance "challenges" rather than adoption barriers is consistent with its institutional mission. + +## Curator Notes (structured handoff for extractor) +PRIMARY CONNECTION: Session 14 claim candidate on "regulatory capture as sixth institutional failure mode" +WHY ARCHIVED: First confirmed safety-oriented submission to the Lords inquiry, before April 20 deadline. Moderates the pure "regulatory capture" framing — safety evidence is entering the record. +EXTRACTION HINT: Do not extract now. Read the full submission after April 20. The key question: does the ALI submission explicitly reference the clinical AI failure mode literature (automation bias, de-skilling, NOHARM)? If yes, that's a distinct extractable claim: "institutional acknowledgment of clinical AI failure modes reached Parliament via Lords inquiry." If no, the submission is less notable. -- 2.45.2 From dcbc1043fee0460f6ee52b6a5ef7da95c6cc81c9 Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Mon, 30 Mar 2026 04:30:51 +0000 Subject: [PATCH 3/5] extract: 2026-03-30-cap-obbba-implementation-timeline Pentagon-Agent: Epimetheus <3D35839A-7722-4740-B93D-51157F7D5E70> --- ...26-03-30-cap-obbba-implementation-timeline.md | 16 +++++++++++++++- 1 file changed, 15 insertions(+), 1 deletion(-) diff --git a/inbox/queue/2026-03-30-cap-obbba-implementation-timeline.md b/inbox/queue/2026-03-30-cap-obbba-implementation-timeline.md index 8f59b3162..52bf2576c 100644 --- a/inbox/queue/2026-03-30-cap-obbba-implementation-timeline.md +++ b/inbox/queue/2026-03-30-cap-obbba-implementation-timeline.md @@ -7,9 +7,13 @@ date: 2026-01-01 domain: health secondary_domains: [] format: policy-analysis -status: unprocessed +status: null-result priority: medium tags: [OBBBA, Medicaid, work-requirements, implementation-timeline, CMS, coverage-loss, January-2027] +processed_by: vida +processed_date: 2026-03-30 +extraction_model: "anthropic/claude-sonnet-4.5" +extraction_notes: "LLM returned 0 claims, 0 rejected by validator" --- ## Content @@ -57,3 +61,13 @@ The "triple compression" scenario (coverage loss + benefit cuts + GLP-1 deauthor PRIMARY CONNECTION: Active thread on Medicaid compression / GLP-1 coverage loss WHY ARCHIVED: Corrects a factual error in the active research thread (October 2026 → January 2027 for work requirements). Critical for accurate timeline on any claims about OBBBA coverage loss. EXTRACTION HINT: Do not extract as a standalone claim. Use to correct the timeline in any claim mentioning OBBBA coverage loss. If a claim was drafted with "October 2026" as the date, correct to "January 1, 2027" (or "mid-2026 in early-implementing states via 1115 waivers"). + + +## Key Facts +- OBBBA Section 71110 (FMAP limits for emergency Medicaid for immigrants) becomes effective October 1, 2026 +- OBBBA work requirements for Medicaid become effective January 1, 2027 +- CMS must provide guidance to states by June 1, 2026 +- States must conduct member outreach June 30 - August 31, 2026 +- States can request extensions until December 31, 2028 if demonstrating good faith effort +- States may implement work requirements earlier via 1115 waiver process +- Center for American Progress, AMA, CHCS, King & Spalding, and Ballotpedia News all confirm January 2027 timeline -- 2.45.2 From dbf6046e84445a4c1c6e97e098eea31b8b6d18e6 Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Mon, 30 Mar 2026 04:52:19 +0000 Subject: [PATCH 4/5] pipeline: archive 1 source(s) post-merge Pentagon-Agent: Epimetheus <3D35839A-7722-4740-B93D-51157F7D5E70> --- ...03-30-cap-obbba-implementation-timeline.md | 59 +++++++++++++++++++ 1 file changed, 59 insertions(+) create mode 100644 inbox/archive/general/2026-03-30-cap-obbba-implementation-timeline.md diff --git a/inbox/archive/general/2026-03-30-cap-obbba-implementation-timeline.md b/inbox/archive/general/2026-03-30-cap-obbba-implementation-timeline.md new file mode 100644 index 000000000..2ef785013 --- /dev/null +++ b/inbox/archive/general/2026-03-30-cap-obbba-implementation-timeline.md @@ -0,0 +1,59 @@ +--- +type: source +title: "OBBBA Implementation Timeline: Work Requirements January 2027, Not October 2026 — Center for American Progress Analysis" +author: "Center for American Progress" +url: https://www.americanprogress.org/article/when-do-the-one-big-beautiful-bill-acts-health-care-provisions-go-into-effect/ +date: 2026-01-01 +domain: health +secondary_domains: [] +format: policy-analysis +status: processed +priority: medium +tags: [OBBBA, Medicaid, work-requirements, implementation-timeline, CMS, coverage-loss, January-2027] +--- + +## Content + +**Center for American Progress policy analysis** of the OBBBA (One Big Beautiful Bill Act) implementation timeline for healthcare provisions. + +**Key timeline corrections (correcting Session 13-14 understanding):** + +| Provision | Date | Notes | +|---|---|---| +| CMS guidance to states | June 1, 2026 | HHS must provide definitions and clarifications | +| Member outreach by states | June 30 – August 31, 2026 | Required via mail + one additional channel | +| Section 71110 effective | October 1, 2026 | FMAP limits for emergency Medicaid for immigrants — NOT work requirements | +| **Work requirements effective** | **January 1, 2027** | States must implement by this date | +| Extension deadline | December 31, 2028 | For states demonstrating "good faith effort" | +| Early implementation | Anytime via 1115 waiver | States may choose to implement sooner | + +**Key correction:** The October 1, 2026 date referenced in Sessions 12-13 was for Section 71110 (FMAP limits for emergency Medicaid for certain immigrants), NOT for work requirements. The work requirements themselves begin January 1, 2027. + +**Also cited:** +- AMA summary of OBBBA healthcare provisions (ama-assn.org) +- Center for Health Care Strategies summary of federal work requirements (chcs.org) +- King & Spalding healthcare industry analysis +- Ballotpedia News: mandatory work requirements timeline (January 23, 2026) + +**Coverage loss mechanism revised:** +The "triple compression" scenario (coverage loss + benefit cuts + GLP-1 deauthorization) for the Medicaid population begins in earnest at January 1, 2027, not October 2026. However, states implementing early via 1115 waivers could trigger coverage loss sooner. + +## Agent Notes + +**Why this matters:** Factual correction to an active thread. Sessions 12-14 referenced "semi-annual redeterminations beginning October 1, 2026" as the first coverage loss trigger. This was wrong. The actual work requirements start January 1, 2027. The October date is a different provision. This affects the timeline on the "triple compression" claim candidate. + +**What surprised me:** The 1115 waiver pathway for early implementation. States that are eager to implement work requirements (primarily Republican-led states with large Medicaid expansion populations) can move faster than January 2027 via the existing 1115 waiver process. This means the first coverage losses could occur in 2026 in some states even while the national implementation date is January 2027. + +**What I expected but didn't find:** State-level implementation plans or filed 1115 waivers. The early-implementation pathway is important to track but no specific state has yet filed (as of this search). + +**KB connections:** +- [[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk]] — Medicaid coverage contraction affects the at-risk population most likely to benefit from VBC investments in preventive care + +**Extraction hints:** This source is primarily a factual correction to the claim candidate's timeline, not a new claim. The extractor should note: "triple compression" first mechanism = **January 1, 2027** (not October 2026), with potential early-state 1115 waiver acceleration. + +**Context:** Center for American Progress is a progressive policy organization. The OBBBA analysis is factually based (legal text interpretation), not ideological. Confirm key dates against AMA and King & Spalding sources which are cited. + +## Curator Notes (structured handoff for extractor) +PRIMARY CONNECTION: Active thread on Medicaid compression / GLP-1 coverage loss +WHY ARCHIVED: Corrects a factual error in the active research thread (October 2026 → January 2027 for work requirements). Critical for accurate timeline on any claims about OBBBA coverage loss. +EXTRACTION HINT: Do not extract as a standalone claim. Use to correct the timeline in any claim mentioning OBBBA coverage loss. If a claim was drafted with "October 2026" as the date, correct to "January 1, 2027" (or "mid-2026 in early-implementing states via 1115 waivers"). -- 2.45.2 From eb3126040b0ad85a70f808bf11b136d167d5b0ea Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Mon, 30 Mar 2026 04:31:53 +0000 Subject: [PATCH 5/5] extract: 2026-03-30-jacc-cardiometabolic-treatment-control-rates-1999-2023 Pentagon-Agent: Epimetheus <3D35839A-7722-4740-B93D-51157F7D5E70> --- ...ilability-is-not-the-binding-constraint.md | 27 +++++++++++++++++++ ...bolic-treatment-control-rates-1999-2023.md | 15 ++++++++++- 2 files changed, 41 insertions(+), 1 deletion(-) create mode 100644 domains/health/only-23-percent-of-treated-us-hypertensives-achieve-blood-pressure-control-demonstrating-pharmacological-availability-is-not-the-binding-constraint.md diff --git a/domains/health/only-23-percent-of-treated-us-hypertensives-achieve-blood-pressure-control-demonstrating-pharmacological-availability-is-not-the-binding-constraint.md b/domains/health/only-23-percent-of-treated-us-hypertensives-achieve-blood-pressure-control-demonstrating-pharmacological-availability-is-not-the-binding-constraint.md new file mode 100644 index 000000000..f324b9f76 --- /dev/null +++ b/domains/health/only-23-percent-of-treated-us-hypertensives-achieve-blood-pressure-control-demonstrating-pharmacological-availability-is-not-the-binding-constraint.md @@ -0,0 +1,27 @@ +--- +type: claim +domain: health +description: "Despite decades of effective generic antihypertensives, BP control rates among treated patients reached only 23.4% in 2021-2023, and simultaneous control of hypertension, diabetes, and hyperlipidemia never exceeded 30% from 1999-2023" +confidence: proven +source: JACC longitudinal study 1999-2023, NHANES nationally representative data +created: 2026-03-30 +attribution: + extractor: + - handle: "vida" + sourcer: + - handle: "jacc-study-authors" + context: "JACC longitudinal study 1999-2023, NHANES nationally representative data" +--- + +# Only 23 percent of treated US hypertensives achieve blood pressure control demonstrating pharmacological availability is not the binding constraint in cardiometabolic disease management + +The JACC study tracking 1999-2023 NHANES data reveals a striking failure mode in US cardiometabolic disease management. Among patients already receiving treatment for hypertension, only 23.4% (95% CI: 21.5%-25.2%) achieved blood pressure control by 2021-2023 criteria. More dramatically, the proportion of individuals with all three conditions (hypertension, diabetes, hyperlipidemia) achieving simultaneous control never exceeded 30% at any point during the 24-year study period, despite all three conditions having effective, affordable generic medications available throughout this timeframe (antihypertensives since 1980s, statins since late 1990s, metformin since decades prior). The study explicitly notes that 'treatment and control of these conditions improved during the 2000s, but progress has plateaued in subsequent years,' indicating this is not a problem of insufficient time for diffusion. This 76.6% treatment failure rate among patients already prescribed medication demonstrates that the binding constraint is not drug availability, efficacy, or cost, but rather the behavioral, social, and structural factors that determine medication adherence, lifestyle modification, and care continuity. The plateau in control rates despite continued awareness campaigns and clinical guideline updates suggests these non-pharmacological barriers are not being addressed by the current healthcare delivery model. + +--- + +Relevant Notes: +- [[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]] +- [[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action]] + +Topics: +- [[_map]] diff --git a/inbox/queue/2026-03-30-jacc-cardiometabolic-treatment-control-rates-1999-2023.md b/inbox/queue/2026-03-30-jacc-cardiometabolic-treatment-control-rates-1999-2023.md index 2e1a9d2d2..fad5ca761 100644 --- a/inbox/queue/2026-03-30-jacc-cardiometabolic-treatment-control-rates-1999-2023.md +++ b/inbox/queue/2026-03-30-jacc-cardiometabolic-treatment-control-rates-1999-2023.md @@ -7,9 +7,13 @@ date: 2025-10-01 domain: health secondary_domains: [] format: journal-article -status: unprocessed +status: processed priority: high tags: [hypertension, treatment-adherence, control-rates, cardiometabolic, diabetes, hyperlipidemia, United-States, SDOH, behavioral-health, JACC] +processed_by: vida +processed_date: 2026-03-30 +claims_extracted: ["only-23-percent-of-treated-us-hypertensives-achieve-blood-pressure-control-demonstrating-pharmacological-availability-is-not-the-binding-constraint.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -55,3 +59,12 @@ Despite the availability of effective generic medications for all three conditio PRIMARY CONNECTION: [[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]] WHY ARCHIVED: Provides the clinical-operational evidence for Belief 2 — drugs that work are not achieving outcomes at population level. The 23.4% control rate is the single most striking number for the "medicine fails despite availability" argument. EXTRACTION HINT: Extract as a claim about cardiometabolic risk factor control failure, explicitly framing the 23.4% control rate as evidence that behavioral/SDOH barriers overwhelm pharmacological availability. Extract alongside the hypertension mortality doubling claim (queue/2026-03-30-jacc-cvd-mortality-trends-1999-2023.md) — they form a cause/effect pair. + + +## Key Facts +- Hypertension affects 1 in 2 US adults under 2017 ACC/AHA criteria +- Hypertension prevalence: 23.4% ages 18-39, 52.5% ages 40-59, 71.6% ages 60+ +- Hypertension prevalence showed little change between 2009 and 2023 +- Among treated hypertensive patients, only 23.4% (95% CI: 21.5%-25.2%) achieved BP control in 2021-2023 +- Simultaneous control of hypertension, diabetes, and hyperlipidemia never exceeded 30% between 1999-2023 +- Treatment and control rates improved during 2000s but plateaued in subsequent years -- 2.45.2